Professor Tim Maughan outlines the flagship work of the FOCUS4 trials, whose results were presented this weekend at the European Society of Medical Oncology (ESMO) annual meeting
According to new research led by NDPH, Chinese people who regularly drink alcohol have significantly greater risks of developing severe liver diseases, such as cancer.
The latest results from the multi-arm FOCUS4 trial, led by Tim Maughan at the University of Oxford, has shown that the drug adavosertib has promising activity in bowel cancer patients
A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood cancers.
A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.
A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.
Research from Dr Brian Nicholson and colleagues outlines how routine clinical tests could be widely used to estimate the risk of cancer for people visiting their GPs with unexpected weight loss.
Prostate Cancer UK have invested \u00a31.7 million into five immunotherapy projects, including two from Profs Kate Vallis, Richard Bryant and Eileen Parkes at the University of Oxford. Read about their funded work.
Optellum, a lung health start-up in Oxford, aims to redefine early interception of lung cancer using artificial intelligence (AI) decision support software.
Read their introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers.
The first patient has been dosed using new drug PORT-2 in Oxford, which hopes to improve treatment options for melanoma and Non-Small Cell Lung Cancer (NSCLC) and resensitise patients with checkpoint therapy-resistant tumours
New research from Ross Chapman\u2019s lab has discovered the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.
Our new brand represents how Oxford researchers are working across disciplines to \r\ntranslate their discoveries into better care for cancer patients. Meet the new brand and the people behind it.
A new artificial intelligence software that will help doctors to make quicker and more accurate decisions when diagnosing potentially cancerous lung lesions, has received major government funding.
A new study from the Newstead group at the Department of Biochemistry has solved the structure of the human folate transporter, paving the way for improved anticancer drugs.
A new pan-divisional initiative has launched at the University of Oxford. Bringing together the collective force of cancer research, outreach and care that happen across the city of Oxford.
Botnar Research Centre researchers have developed standalone long-read sequencing of single cells technology that could open new avenues into the causes of diseases like cancer.
![\"Person](\"https://www.cancer.ox.ac.uk/news/focus4-a-flagship-trial-in-colorectal-cancer/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n